Indeed Chilly, with the right kind of management dedicated to get Nicosan back to production, XKEM could be worth what a penny stock should be, just by virtue of its potential to generate revenue alone. XKEM may be beaten hard but not dead. It has been seriously exploited by wolves in sheep's skin. Enron, your favorite comparison, is initiated and spear-headed to cheat on investors from day one. That, in my view, is the biggest difference.
News 
Market Data 
Discover 
